Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Am J Hematol. 2018 Dec 10;94(2):240–248. doi: 10.1002/ajh.25366

Figure 1: BMP2 is not regulated by EPO and is not required for hepcidin suppression by EPO.

Figure 1:

(A-B) Bmp2 endothelial CKO (Bmp2fl/fl;Tek-Cre+) and littermate Cre- control male (blue circles) and female mice (red triangles) were sacrificed at 8 weeks of age (n=3–5 per sex per group). Levels of (A) serum and (B) liver BMP2 were quantitated by ELISA. (C-G) Bmp2fl/fl;Tek-Cre+ and littermate Cre- control male (blue circles, n=3–5 per group) and female (red triangles, n=6–8 per group) mice at 6 weeks of age were injected with PBS or EPO (200 U per mouse) and tissues were collected after 15 hours to determine relative (C) bone marrow erythroferrone (Erfe), (D) liver Bmp2, and (G) liver hepcidin (Hamp) mRNA levels by qRT-PCR. Transcript levels were normalized to Rpl19. (E) Liver and (F) serum BMP2 protein levels in female Cre- animals were determined by ELISA. Values represent mean ± SEM. **P<0.01, ***P<0.001 relative to the respective Cre- controls or PBS-treated controls of the same genotype by Student’s t test. Fold-change relative to PBS treated controls of the same genotype as calculated by 2-ΔΔCt are reported in panel G.